Hiroshi Ishihara

Hiroshi Ishihara specializes in the healthcare and life sciences industry. He handles many commercial transactions, such as M&A of pharmaceutical companies and license agreements, and has extensive experience in international and domestic M&A transactions. He also advises clients on regulations relating to drugs, medical devices, and regenerative medicine.

Admitted in Japan (2000); Admitted in California (2006); Admitted in New York (2007); Visiting Attorney at Kirkland & Ellis LLP (2005 - 2006); Seconded to the Bank of Japan and a general trading company in Japan

Dai-ichi Tokyo Bar Association (Japan), 2000; State Bar of California (USA), 2006; New York State Bar Association (USA), 2007; Advisor to the Medical Affairs Study Group of the Japan Pharmaceutical Industry Legal Affairs Association (Japan)

“Digital Healthcare 2023 – Japan” (Chambers Global Practice Guide, 2023); “Amendment to Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices” (LexisNexis 2022); “Legal Matters regarding Life Sciences and Health Care - Navigation regarding Regulations, Intellectual Properties and Corporate Matters (Second Edition)” (Shoji-homu 2020)